Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green. Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. Real-time analyst ratings, insider transactions, earnings data, and more. Reports are indicating that there were more than several insider trading activities at ZNTL starting from Gallagher Cam, who sale 8,501 shares at the price of $19.96 back on Feb 14. After this action, Gallagher Cam now owns 491,270 shares of Zentalis Pharmaceuticals Inc., valued at $169,706 using the latest closing price.

On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category. According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. We present 13D/G filings separately from the 13F filings because of the different treatement by the SEC. 13D/G filings can be filed by groups of investors , whereas 13F filings cannot. This results in situations where an investor may file a 13D/G reporting one value for the total shares , but then file a 13F reporting a different value for the total shares . This means that share ownership of 13D/G filings and 13F filings are oftentimes not directly comparable, so we present them separately.

Zentalis Pharmaceuticals to Participate in the Stifel 2022 Healthcare Conference

Sign-up to receive the latest news and ratings for Zentalis Pharmaceuticals and its competitors with MarketBeat’s FREE daily newsletter. The P/E ratio of Zentalis Pharmaceuticals is -3.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. MarketBeat has tracked 1 news article for Zentalis Pharmaceuticals this week, compared to 1 article on an average week.

• Eventide Asset Management LLC increased its stake in shares of Zentalis Pharmaceuticals by 85.4% during the 3rd quarter.
• © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.
• Turning to the stock’s technical picture we see that short term indicators suggest on average that ZNTL is a 50% Sell.
• ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
• Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
• Short interest in Zentalis Pharmaceuticals has recently increased by 0.87%, indicating that investor sentiment is decreasing.

According to analysts’ consensus price target of $43.44, Zentalis Pharmaceuticals has a forecasted upside of 149.5% from its current price of $17.41. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.

Eventide Asset Management LLC now owns 1,861,000 shares of the company’s stock worth $40,309,000 after purchasing an additional 857,000 shares in the last quarter. Sofinnova Investments Inc. increased its position in Zentalis Pharmaceuticals by 77.6% during the 3rd quarter. Sofinnova Investments Inc. now owns 583,357 shares of the company’s stock valued at $12,636,000 after buying an additional 254,960 shares in the last quarter.

ZNTL’s current price about 1.74% and -7.74% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index currently prints 48.86, while 7-day volatility ratio is 6.25% and 7.16% in the 30-day chart. Further, Zentalis Pharmaceuticals Inc. has a beta value of 0, and an average true range of 1.16. A look at the stock’s price movement, the close in the last trading session was $17.57, moving within a range at $16.685 and $18.06. Turning to its 52-week performance, $51.54 and $15.55 were the 52-week high and 52-week low respectively.

6 best offshore banks for opening accounts, Inc. reported Q4 EPS of ($0.87), $0.19 better than the analyst estimate of ($1.06). Zentalis Pharmaceuticals has been rated by HC Wainwright, and Stifel Nicolaus in the past 90 days. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. CompareZNTL’s historical performanceagainst its industry peers and the overall market.

The Company has announced it will collaborate with Pfizer on a Phase 1/2 dose escalation study of azenosertib in combination with encorafenib and cetuximab in patients with BRAF V600E-mutated colorectal cancer. The Company initiated enrollment in this clinical trial in the first quarter of 2023. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations.

RATIOS/PROFITABILITY

And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. ZN-d5 is a selective, oral small molecule inhibitor of B-cell lymphoma 2 (BCL-2), which is currently being evaluated in patients with hematologic malignancies. BCL-2 is a protein that plays a critical role in the regulation of cell death, known as apoptosis. The overexpression of BCL-2 is frequently detected in numerous cancer types, which prevents apoptosis of cancer cells. Utilizing our medicinal chemistry expertise, we have designed ZN-d5 to have best in class potency, selectivity and pharmacokinetic properties. Azenosertib is a potentially first-in-class and best-in-class small molecule Wee1 inhibitor in development for the treatment of cancer.

Eventide Asset Management LLC increased its stake in shares of Zentalis Pharmaceuticals by 85.4% during the 3rd quarter. Eventide Asset Management LLC now owns 1,861,000 shares of the company’s stock worth $40,309,000 after purchasing an additional 857,000 shares during the last quarter. Ensign Peak Advisors Inc increased its stake in shares of Zentalis Pharmaceuticals by 81.8% during the 3rd quarter. Ensign Peak Advisors Inc now owns 151,853 shares of the company’s stock worth $3,289,000 after purchasing an additional 68,327 shares during the last quarter.

Exelixis Inc. (EXEL) Shares Down Despite Recent Market Volatility

In addition, Zentalis Pharmaceuticals Inc. saw -13.75% in overturn over a single year, with a tendency to cut further losses. Jefferies gave a rating of “Buy” to ZNTL, setting the target price at $120 in the report published on October 07th of the previous year. A brief financial summary of Zentalis Pharmaceuticals Llc as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

Since 1988 it has more than doubled the S&P 500 with an average gain of +24.52% per year. These returns cover a period from January 1, 1988 through February 6, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return.

Zentalis Pharmaceuticals sets IPO terms, to be valued at up to $592 million

Inhibition of Wee1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death. Currently, there are no FDA-approved Wee1 inhibitors, and we have designed ZN-c3 to have advantages over other investigational therapies, including superior selectivity and pharmacokinetic properties. 52 week low is the lowest price of a stock in the past 52 weeks, or one year. Zentalis Pharmaceuticals Inc 52 week low is $15.55 as of April 11, 2023.

• Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• The overexpression of BCL-2 is frequently detected in numerous cancer types, which prevents apoptosis of cancer cells.
• This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system.

The average of price targets set by Wall Street analysts indicates a potential upside of 170.4% in Zentalis Pharmaceuticals, Inc. . According to analysts, Zentalis Pharmaceuticals’s stock has a predicted upside of 118.78% based on their 12-month price targets. Enterprise Value is a measure of a company’s total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company’s balance sheet. Market cap or market capitalization is the total market value of all of a company’s outstanding shares. High-growth stocks tend to represent the technology, healthcare, and communications sectors.

Similar to SIPC protection, this additional insurance does not protect against a loss in the market value of securities. This means that this stock is suited as a new addition to your portfolio as trading bullish markets is always a lot easier. Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more. Companies will collaborate on Phase 1/2 dose escalation study of ZN-c3, a selective Wee1 inhibitor, in combination with encorafenib and cetuximab in patients with BRAF V600E-mutated colorectal cancer …

As of April 2023 Zentalis Pharmaceuticals has a market cap of $1.03 Billion. This makes Zentalis Pharmaceuticals the world’s 4583th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company’s outstanding shares and is commonly used to measure how much a company is worth. We sell different types of products and services to both investment professionals and individual investors.

The average trading volume of ZNTL on March 24, 2023 was 553.04K shares. The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company. In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares. The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Market cap, also known as market capitalization, is the total market value of a company.

Style is an https://1investing.in/ factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated. Storylines Follow Bloomberg reporters as they uncover some of the biggest financial crimes of the modern era. This documentary-style series follows investigative journalists as they uncover the truth. Sign Up NowGet this delivered to your inbox, and more info about our products and services. 19.90% of the stock of Zentalis Pharmaceuticals is held by insiders.

Data shows ZNTL’s intraday price has changed 2.28% in last session and -63.51% over the past year. Looking at another peer, we see that Rogers Corporation price has gained 1.34% on the day. Moreover, AstraZeneca PLC is also up 0.40% in trading on the day while keeping a an uptrend of 7.89% over the past year. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are up 0.36% and 0.01% respectively in the last trading.

It’s calculated by multiplying the current market price by the total number of shares outstanding. H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Zentalis Pharmaceuticals (ZNTL – Research Report) today and set a price target of $55.00. The company’s shares closed yesterday at $18.39.Fein covers the Healt…